­
­
­
­

Inventi Impact: Advanced Dosaging

Articles

  • Inventi:pad/81/12
    IMMUNOSUPPRESSIVE ACTIVITY OF SIZE-CONTROLLED PEG-PLGA NANOPARTICLES CONTAINING ENCAPSULATED CYCLOSPORINE A
    30-Jun-2012 Research 2012 : July - September
    Li Tang, Jamil Azzi, Mincheol Kwon, Marwan Mounayar, Rong Tong, Qian Yin,\r\nRobert Moore, Nikolaos Skartsis, Timothy M Fan, Reza Abdi, Jianjun Cheng

    We encapsulated cyclosporine A (CsA) in poly(ethylene glycol)-b-poly(d,l-lactide-co-glycolide) (PEG-PLGA) nanoparticles (NPs)\r\nby nanoprecipitation of CsA and PEG-PLGA. The resulting CsA/PEG-PLGA-NPs were <100nm in diameter with a narrow\r\nparticle size distribution. The NP size could be controlled by tuning the polymer concentration, solvent, or water/solvent ratio\r\nduring formulation. The PEGylated NPs maintained non-aggregated in salt solution. Solid NPs lyoprotected with bovine serum\r\nalbumin were prepared for the convenience of storage and transportation. The release kinetics of CsA (55.6% released on Day 1)\r\nshowed potential for maintaining therapeutic CsA concentrations in vivo. In T-cell assays, both free CsA and CsA/PEG-PLGA-NPs\r\nsuppressed T-cell proliferation and production of inflammatory cytokines dose dependently. In a mixed lymphocyte reaction assay,\r\nthe IC50 values for free CsA and CsA/PEG-PLGA-NPs were found to be 30 and 35 ng/mL, respectively. This nanoparticulate CsA\r\ndelivery technology constitutes a strong basis for future targeted delivery of immunosuppressive drugs with improved efficiency\r\nand potentially reduced toxicity.

    How to Cite this Article
    CC Compliant Citation: Li Tang, Jamil Azzi, Mincheol Kwon, et al.,\r\nâ??Immunosuppressive Activity of Size-Controlled PEG-PLGA\r\nNanoparticles Containing Encapsulated Cyclosporine A,â? Journal\r\nof Transplantation, vol. 2012, Article ID 896141, 9 pages, 2012.\r\ndoi:10.1155/2012/896141.
    Download Full Text